⚖️ CagriSema 10mg — Synergistic Dual-Pathway Support for Weight & Metabolic Optimization

Experience the next frontier in peptide synergy with CagriSema, a powerful combination of Cagrilintide (5mg) and Semaglutide (5mg). This dual-pathway formulation merges amylin and GLP-1 receptor agonism to deliver enhanced satiety, appetite suppression, and metabolic regulation.

🧬 Clinical studies show that CagriSema outperforms monotherapy peptides in weight loss, glycemic control, and cardiovascular markers—making it a standout in advanced metabolic protocols.

---

Key Benefits:

• ⚖️ Accelerates Fat Loss & Body Recomposition

• 💉 Improves Insulin Sensitivity & Glucose Regulation

• 🍽️ Enhances Satiety & Reduces Cravings

• ❤️ Supports Cardiovascular & Bone Health

---

Ideal for advanced metabolic support, body composition refinement, and research into synergistic peptide therapies.

📊 Research Outcomes

• Average weight loss: 23–24.4% (vs. 15–17% with Semaglutide alone)

• Improved glucose control, bone density, and cardiovascular markers

• 91.9% of participants achieved ≥5% weight reduction in trials.

This product is sold as a research chemical only and not for human use.